Immunosenescence in Aging and Cancer: Molecular Mechanisms, Tumor Microenvironment Remodeling, and Therapeutic Implications
6 affiliations
- 1Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan
- 2Department of Biotechnology and Genetic Engineering, Hazara University, Mansehra 21300, Pakistan
- 3Gomal Center of Biotechnology and Biochemistry (GCBB), Gomal University, Dera Ismail Khan 29050, Pakistan
- 4Department of Biosciences Biotechnologies and Environment, University of Bari Aldo Moro, 70125 Bari, Italy
- 5Department of Medicine and Surgery, LUM University, 70010 Casamassima, Italy
- 6Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, Italy
Abstract
Immunosenescence is the decline in immune function with age, which influences cancer progression and treatment outcomes. This process arises from multiple, interconnected molecular and cellular alterations. Among these, mitochondrial dysfunction in aged immune cells may contribute to impaired immune function through altered metabolism, redox imbalance, and inflammatory signaling. This review discusses mitochondrial alterations alongside other age-related mechanisms that shape immune cell function and may promote cancer development. We examine how DNA damage, telomere shortening, epigenetic changes, altered proteostasis, and mitochondrial dysfunction contribute to immune aging and potentially compromise antitumor immunity. The aged tumor microenvironment is characterized by increased immunosuppressive cell populations, persistent inflammatory signaling, and metabolic alterations that can influence tumor development and therapeutic responses. We also examine how aging affects response to current cancer immunotherapies. While some treatments show comparable efficacy in older and younger patients, others may be less effective in the context of age-related immune dysfunction. Older patients may also experience distinct toxicity profiles that require careful clinical management. Understanding how mitochondrial alterations interact with other mechanisms of aging to shape immunosenescence may help identify therapeutic strategies for cancer in older adults. Future approaches may combine interventions targeting mitochondrial fitness, chronic inflammation, and cellular senescence. However, clinical studies specifically designed to include older populations are needed to establish the relevance of these mechanisms in cancer and to guide age-specific therapeutic strategies.
Related
- Malignant remodeling of the bone marrow microenvironment in acute myeloid leukemia: mechanisms and therapeutic implications
- Emerging Roles of ETV4 in Tumor Microenvironment Remodeling: Mechanisms and Therapeutic Targeting
- Metabolic Dysfunction and T-Cell Exhaustion in Colorectal Cancer: Mechanisms, Microenvironment Remodeling, and Therapeutic Opportunities
- Long non-coding RNA-mediated stress adaptation and immune remodeling in non-small cell lung cancer: molecular mechanisms and therapeutic implications
- Osteoimmunology and bone microenvironment remodeling in osteoporosis: mechanisms and translational perspectives
BibTeX
@article{zarlashat2026immunosenescence,
title = {{Immunosenescence in Aging and Cancer: Molecular Mechanisms, Tumor Microenvironment Remodeling, and Therapeutic Implications}},
author = {Yusra Zarlashat and Syed Salman Shah and Seerat-Uz-Zahra and Rosa Di Lorenzo and Anna Picca},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16101487},
url = {https://www.mdpi.com/2218-273X/16/10/1487},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immunosenescence in Aging and Cancer: Molecular Mechanisms, Tumor Microenvironment Remodeling, and Therapeutic Implications
AU - Yusra Zarlashat
AU - Syed Salman Shah
AU - Seerat-Uz-Zahra
AU - Rosa Di Lorenzo
AU - Anna Picca
PY - 2026
DA - 2026/10/01
JO - Biomolecules
DO - 10.3390/biom16101487
UR - https://www.mdpi.com/2218-273X/16/10/1487
AB - Immunosenescence is the decline in immune function with age, which influences cancer progression and treatment outcomes. This process arises from multiple, interconnected molecular and cellular alterations. Among these, mitochondrial dysfunction in aged immune cells may contribute to impaired immune function through altered metabolism, redox imbalance, and inflammatory signaling. This review discusses mitochondrial alterations alongside other age-related mechanisms that shape immune cell function and may promote cancer development. We examine how DNA damage, telomere shortening, epigenetic changes, altered proteostasis, and mitochondrial dysfunction contribute to immune aging and potentially compromise antitumor immunity. The aged tumor microenvironment is characterized by increased immunosuppressive cell populations, persistent inflammatory signaling, and metabolic alterations that can influence tumor development and therapeutic responses. We also examine how aging affects response to current cancer immunotherapies. While some treatments show comparable efficacy in older and younger patients, others may be less effective in the context of age-related immune dysfunction. Older patients may also experience distinct toxicity profiles that require careful clinical management. Understanding how mitochondrial alterations interact with other mechanisms of aging to shape immunosenescence may help identify therapeutic strategies for cancer in older adults. Future approaches may combine interventions targeting mitochondrial fitness, chronic inflammation, and cellular senescence. However, clinical studies specifically designed to include older populations are needed to establish the relevance of these mechanisms in cancer and to guide age-specific therapeutic strategies.
SN - 2218-273X
ER -